The original amylin drug — approved for 20 years, and the honest foil to the amylin revival. Three points define this entry: (1) it is the founding amylin analog and a genuinely FDA-approved drug (Symlin, 2005) — real, marketed, on-label; (2) but it is modest and niche — small weight loss, three-tim
Pramlintide is the original amylin analog and a long-approved drug (Symlin, FDA 2005) — a synthetic version of amylin, the satiety/glucose hormone co-released with insulin. It works centrally (in the brainstem's area postrema) to suppress post-meal glucagon, slow gastric emptying, and increase satiety, which lowers post-meal glucose spikes and modestly reduces weight. Its honest limits are what define it: HbA1c drops only ~0.3–0.6% and weight loss only ~1–2.3 kg, it must be injected three times daily (at meals, separate from insulin), it's an insulin adjunct (not standalone), it raises hypoglycemia risk when combined with insulin, and nausea is the main side effect. Those limits — modest efficacy, heavy injection burden — are exactly why it was underused and eclipsed by once-weekly GLP-1 drugs. But it proved the amylin concept, and the pathway has now come roaring back through long-acting, once-weekly successors (Cagrilintide, Petrelintide, Eloralintide) and amylin/GLP-1 combos (CagriSema, Amycretin). Pramlintide is the approved-but-modest grandfather of a suddenly-hot class.
availability limited; primarily a US drug.
An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.
A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated July 2026 (pramlintide's status is stable/old; the moving part is the successor class — re-check Cagrilintide/Petrelintide/Eloralintide milestones).
Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.
A neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.